Pronota raises an additional EUR 1.5 million in a final close of its Series B financing totaling EUR 7.9 million
The results obtained so far in its cardio-renal and other programs provide validation of Pronota's technology. Pronota now addresses a range of significant commercial opportunities, and is aiming to have its first product ready for launch in 2012.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.